Janux Therapeutics, Inc. (NASDAQ:JANX) Stake Boosted by Janus Henderson Group PLC

Janus Henderson Group PLC lifted its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 40.0% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,523,406 shares of the company's stock after purchasing an additional 721,563 shares during the quarter. Janus Henderson Group PLC owned about 4.81% of Janux Therapeutics worth $114,587,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. Plato Investment Management Ltd lifted its holdings in Janux Therapeutics by 18.7% in the 3rd quarter. Plato Investment Management Ltd now owns 1,186 shares of the company's stock valued at $54,000 after purchasing an additional 187 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Janux Therapeutics by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company's stock valued at $87,000 after buying an additional 339 shares during the period. Amalgamated Bank boosted its position in Janux Therapeutics by 61.1% during the second quarter. Amalgamated Bank now owns 970 shares of the company's stock worth $41,000 after acquiring an additional 368 shares during the last quarter. Summit Securities Group LLC acquired a new position in Janux Therapeutics in the 2nd quarter valued at $29,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Janux Therapeutics during the 2nd quarter worth $151,000. Hedge funds and other institutional investors own 75.39% of the company's stock.

Wall Street Analysts Forecast Growth

JANX has been the subject of a number of recent analyst reports. William Blair reaffirmed an "outperform" rating on shares of Janux Therapeutics in a research report on Tuesday. Cantor Fitzgerald reiterated an "overweight" rating and issued a $100.00 target price on shares of Janux Therapeutics in a report on Thursday, November 7th. HC Wainwright lifted their target price on Janux Therapeutics from $63.00 to $70.00 and gave the company a "buy" rating in a report on Tuesday. UBS Group began coverage on Janux Therapeutics in a report on Thursday, October 24th. They issued a "buy" rating and a $69.00 target price on the stock. Finally, Leerink Partnrs upgraded Janux Therapeutics to a "strong-buy" rating in a report on Friday, November 22nd. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $79.90.

Insider Activity at Janux Therapeutics

In other news, CEO David Alan Campbell sold 25,000 shares of the company's stock in a transaction that occurred on Friday, September 27th. The stock was sold at an average price of $46.31, for a total transaction of $1,157,750.00. Following the completion of the transaction, the chief executive officer now directly owns 307,054 shares of the company's stock, valued at approximately $14,219,670.74. This represents a 7.53 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Ventures Xi L.P. Avalon sold 958 shares of the company's stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $46.24, for a total value of $44,297.92. Following the transaction, the insider now directly owns 6,887 shares of the company's stock, valued at $318,454.88. This trade represents a 12.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 460,610 shares of company stock valued at $21,583,666 over the last three months. 29.40% of the stock is owned by insiders.

Janux Therapeutics Stock Performance

Shares of NASDAQ JANX traded down $0.53 during midday trading on Thursday, reaching $66.30. 3,850,105 shares of the company's stock were exchanged, compared to its average volume of 776,717. Janux Therapeutics, Inc. has a 52-week low of $7.79 and a 52-week high of $71.71. The stock has a market capitalization of $3.48 billion, a PE ratio of -58.37 and a beta of 3.29. The business's fifty day moving average price is $50.21 and its two-hundred day moving average price is $45.96.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The business had revenue of $0.44 million for the quarter, compared to analysts' expectations of $1.50 million. The firm's revenue for the quarter was down 82.6% compared to the same quarter last year. Analysts predict that Janux Therapeutics, Inc. will post -1.35 earnings per share for the current fiscal year.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.